- Agenus Inc. is set to unveil significant developments in cancer immunotherapy at a major conference in April 2025.
- Analyst forecasts suggest a potential upside of 236.54% for Agenus Inc. shares.
- GuruFocus estimates indicate an 85.58% potential upside based on the GF Value calculation.
Agenus Inc. (AGEN) is gearing up to present its cutting-edge advancements in cancer immunotherapy at the prestigious American Association for Cancer Research Annual Meeting in April 2025. This event will spotlight groundbreaking data from the NEOASIS trial and an exploratory Phase 1 study, focusing on the efficacy of botensilimab and balstilimab in combating advanced solid tumors.
Wall Street Analysts Forecast
The one-year price targets provided by a cohort of three analysts paint an optimistic picture for Agenus Inc. (AGEN). The average target price stands at $7.00, with projections ranging between a high of $11.00 and a low of $3.00. This average target price suggests a remarkable potential upside of 236.54% from the current trading price of $2.08. For more detailed estimates, visit the Agenus Inc (AGEN, Financial) Forecast page.
Brokerage Recommendations
Consensus from five brokerage firms currently assigns Agenus Inc. (AGEN) an average recommendation score of 2.8, indicating a "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies a Strong Buy and 5 denotes a Sell.
GuruFocus Value Estimates
According to GuruFocus estimates, the projected GF Value for Agenus Inc. (AGEN) in the coming year is calculated at $3.86, reflecting a potential upside of 85.58% from its present price of $2.08. The GF Value represents GuruFocus' fair value estimate, derived from historical trading multiples, past business growth, and future performance projections. For comprehensive data, consult the Agenus Inc (AGEN, Financial) Summary page.
